De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Doximity Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Doximity is de winst gegroeid met een gemiddeld jaarlijks percentage van 37.2%, terwijl de Healthcare Services industrie de winst jaarlijks groeide met 14.8%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 20.3% per jaar. Het rendement op eigen vermogen van Doximity is 17.6%, en het heeft een nettomarge van 32.5%.
Belangrijke informatie
37.2%
Groei van de winst
23.2%
Groei van de winst per aandeel
| Healthcare Services Groei van de industrie | 1.7% |
| Inkomstengroei | 20.3% |
| Rendement op eigen vermogen | 17.6% |
| Nettomarge | 32.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
Sep 23
There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump
Aug 18Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns
Aug 10Doximity Faces Slower Revenue Growth As R&D Costs May Rise
Jul 23Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?
Jul 23At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?
Jul 01Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking
Jun 09Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)
May 17Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal
May 04Doximity: Significant Upside Remains, But Not Until The Growth Story Returns
Apr 29With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For
Apr 16Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Mar 26Doximity: Rating Upgrade To Buy As Outlook Turns Positive
Feb 21We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit
Feb 15What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?
Feb 13Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan
Jan 16Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital
Jan 04Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price
Dec 14Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism
Nov 10Doximity: Adding Value Using AI But Faces Near-Term Risks
Nov 01Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 30Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively
Sep 25Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook
Aug 24Doximity Earnings: Too Many Problems, Sell
Aug 09A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
Jul 29Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching
Jul 09Doximity: Continue To See Positive Upside From Current Stock Level
Jul 05The Returns At Doximity (NYSE:DOCS) Aren't Growing
Jun 21Doximity: Digital Health Play With Strong Fundamentals
Jun 21A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Apr 07Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return
Mar 20Doximity: Good Business But Extremely Overvalued
Feb 18Doximity Q3 Earnings: Disappointing Results
Feb 10Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Dec 25Doximity: On The Right Path To Further Consolidate Market Share
Dec 22Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital
Dec 04Doximity up 16% after fiscal 2023 Q2 beats, FY revenue range includes consensus
Nov 10Doximity, down 9%, falls below IPO price
Oct 12Opbrengsten en kosten
Hoe Doximity geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 494 | 161 | 171 | 83 |
| 31 Mar 24 | 475 | 148 | 170 | 82 |
| 31 Dec 23 | 468 | 138 | 169 | 83 |
| 30 Sep 23 | 448 | 123 | 167 | 84 |
| 30 Jun 23 | 437 | 119 | 166 | 83 |
| 31 Mar 23 | 419 | 113 | 160 | 80 |
| 31 Dec 22 | 402 | 119 | 153 | 76 |
| 30 Sep 22 | 384 | 141 | 146 | 72 |
| 30 Jun 22 | 362 | 148 | 138 | 68 |
| 31 Mar 22 | 344 | 133 | 128 | 62 |
| 31 Dec 21 | 317 | 107 | 114 | 57 |
| 30 Sep 21 | 277 | 57 | 101 | 53 |
| 30 Jun 21 | 243 | 30 | 88 | 47 |
| 31 Mar 21 | 207 | 22 | 78 | 44 |
| 31 Dec 20 | 177 | 14 | 67 | 40 |
| 31 Mar 20 | 116 | 11 | 46 | 32 |
| 31 Mar 19 | 86 | 1 | 40 | 27 |
Kwaliteitswinsten: DOCS heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (32.5%) DOCS } zijn hoger dan vorig jaar (27.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van DOCS is de afgelopen 5 jaar aanzienlijk gegroeid met 37.2% per jaar.
Versnelling van de groei: De winstgroei van DOCS over het afgelopen jaar ( 35.1% ) ligt onder het 5-jarig gemiddelde ( 37.2% per jaar).
Winst versus industrie: De winstgroei DOCS over het afgelopen jaar ( 35.1% ) overtrof de Healthcare Services -sector 13.9%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 17.6% ) van DOCS wordt als laag beschouwd.